Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. - sprookjes - yvandenbroek - TriplyDB

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

http://www.wikidata.org/entity/Q34606479

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses Advances in immunotherapy for melanoma Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.Increased shedding of HU177 correlates with worse prognosis in primary melanoma Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.Targeting immune suppressing myeloid-derived suppressor cells in oncology.Therapy for metastatic melanoma: the past, present, and future.Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.Selection of extreme phenotypes: the role of clinical observation in translational research.Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine.Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).Increased expression of pregnancy up-regulated non-ubiquitous calmodulin kinase is associated with poor prognosis in clear cell renal cell carcinoma The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.Antitumor vaccines, immunotherapy and the immunological constant of rejection Gene-expression profiling in vaccine therapy and immunotherapy for cancer Immunotherapy for melanoma: current status and perspectives.Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.Immunomodulatory cytokines as therapeutic agents for melanoma

P2860

Q24606852-5E550984-78BB-46E7-84A9-B5A93BA96A74 Q24616434-7AD8EDC2-ED83-46F8-8DFE-311CCA670BD4 Q26768558-97330A21-26FA-40D9-8250-A1744CDCFEAB Q26781098-60C1E216-EB26-4CA7-9FB1-4A1FD1A405A4 Q26796316-C5F156D9-EABF-4B3C-9FBF-1D41A8C73B07 Q26824310-064FE6B1-F808-4AD6-AC6C-97AF52DF10E8 Q27004178-94AA68B4-7B03-48A7-896C-B9B1A379F9B5 Q27691824-7506C4F9-716C-4C2A-A233-7D38B20CF327 Q30438965-B0BC37FC-526E-4774-968C-BE6F5208BD04 Q30440347-2A9D19FB-6334-4873-8366-DE67CD6560A2 Q33417698-4FD065FB-D45B-4406-9AAF-C9C5D8ED2150 Q33606102-DFF28C82-1C51-479C-8987-4F539D5BFD4E Q33665758-AE5DEA2E-13CB-49BB-A6F5-A60F220EA6A8 Q33724016-4EB7BC5A-DCEE-4D2A-9BDD-BF04C945E552 Q33753431-3777A02D-2D05-44D8-80EC-BC0F7887DA61 Q34029085-F5ECE3FD-4D1C-452A-9281-BC94F84B76F6 Q34082067-15ABFE96-9A0B-4144-81D2-DB7980D52C1B Q34183225-145F3E2A-32CA-4411-A3C5-AFE16955A24A Q34278609-2E949C3A-7925-4AE5-8861-C02839B2822E Q34350259-07586CE6-145B-40B4-B37C-47DBD5F99791 Q34365135-DBC24DA4-1403-4178-8C62-ACD2A65CE8AE Q34384968-87D7F0CE-6FD9-4BC2-8E5E-6B05E9128784 Q34464096-42338FC2-0FDD-4106-8621-D9F0254577CC Q34514797-3062C892-25D3-4AAD-A9E6-7C79F87E931A Q34572309-AA4286C4-283A-4D28-8815-B69985C44EDC Q34608796-5E4AB9B4-E403-4D16-9934-04099AAE0E1C Q34698033-FA14929C-3AF3-4E46-B248-407B1E6FC962 Q35044419-0F952A67-000D-42D5-B6DA-045564435EB5 Q35377689-014B9E7C-18BD-4C92-AB42-FFBCB0B83E96 Q35621653-0FEDF1B6-B84D-4A22-B932-5504460918BB Q35661491-991F288F-CDB4-417B-9773-3CFBB54C8FBC Q35798966-0BB31241-6F8E-4B02-AEC0-EFD3DE5152EC Q35802508-F6DBAE0E-0253-4804-9A12-AFF7BB620BD6 Q36061606-B9E0F038-7B37-4530-A89A-590B1053CCCD Q36136498-9F945982-BDFA-4FEA-83D5-2D839C30346E Q36138329-11B7EDF9-3B8F-4428-B024-98097DA9A7B6 Q36453216-6B64BF8C-7734-4B76-B7D3-E58B8906905D Q36744566-16BBA08A-B3C5-472F-8052-C5CE5450FF9B Q37024656-98C37140-380D-491B-AA66-FB9BB5CA3DC0 Q37070203-17455398-EF02-4109-BACC-F8A066027E0D

P2860

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

http://www.wikidata.org/entity/Q34606479

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@ast

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@en

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@nl

type

label

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@ast

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@en

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@nl

prefLabel

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@ast

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@en

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@nl

P1433

Q34606479-9C9F6FFD-1AAC-461E-8C8A-019B91F46A34

P1476

Q34606479-43511230-6A26-4513-823B-FE91765C6EDA

P2093

Q34606479-01616DFF-9679-4325-A6EE-857EA38FF9B7

Q34606479-03447297-D275-40AD-9FF2-EB9D608D04F1

Q34606479-231F7DE1-ECE1-4463-A4AC-641F57024956

Q34606479-49AC9D42-B0DD-43D7-88C8-3A0C5F70680A

Q34606479-5D3721A2-31F1-4420-B478-092081E697CD

Q34606479-6E9BDE19-E83D-4DA7-A137-4BEC89730EAD

Q34606479-C5F25E64-3140-4545-AB66-6DDA033579C7

Q34606479-CCCBA1F5-F993-410C-9C47-36AAD9231D10

Q34606479-DF1CE43F-FCF6-4AEE-BFE4-06C8ACC66564

Q34606479-E3A470DC-5301-4652-8577-DA96F9852512

P2860

Q34606479-0080465C-B70E-43BA-953D-98C9133622D8

Q34606479-15AD491C-70F9-4D47-AA2E-B77709406EE1

Q34606479-2CF73059-7FEC-45ED-9B57-4D3B0CC88D11

Q34606479-42EBEDEF-164C-44A9-94BD-B59AEDC136A5

Q34606479-4C7141AE-614F-4D16-9310-1D2820DAE566

Q34606479-4E77E663-4AB3-4B59-BC28-5AE10FDA35C9

Q34606479-59558266-F7EB-4601-8271-CFF20E1B4A89

Q34606479-5F453CB3-1AF0-40EF-9E72-56AC43CA3CE3

Q34606479-61682CB8-9812-40A0-8DA8-ED554DC605BE

Q34606479-6A61E819-1E89-44EE-916D-8037AB20EE5C

P304

Q34606479-1C47761B-714B-4FC5-B733-8C109477324E

P31

Q34606479-8B7EA0FC-2F11-4123-A2BF-FF82FFC7C886

P356

Q34606479-A7A6416D-1B19-4145-86E5-BD05CFD71044

P407

Q34606479-5EDBF852-26EE-4C2B-A456-D250DCF6A37A

P433

Q34606479-B1A7C410-6A39-4D0B-A476-3D3F22990F97

P478

Q34606479-6C945D30-17A7-49D4-92CD-69B8DF119A4C

P577

Q34606479-E210954A-579D-4153-A56A-115B76C44C1F

P698

Q34606479-AA33752E-D2DF-445B-A8A0-B5D0F878A210

P921

Q34606479-429d8cb0-0cc9-4874-aede-8a27ced5cb8b

Q34606479-A4DBB193-D1F6-4CD4-B4EE-5C1DD6A4F58A

P932

Q34606479-7281998B-1BD1-4174-A4C4-67691C36EAB8

P356

JCO.2008.19.1106

P1433

Journal of Clinical Oncology

P1476

Serum vascular endothelial gro ...... gh-dose interleukin-2 therapy.

@en

P2093

Bret Taback

http://www.w3.org/2001/XMLSchema#string

Dae Won Kim

http://www.w3.org/2001/XMLSchema#string

David Stroncek

http://www.w3.org/2001/XMLSchema#string

Ena Wang

http://www.w3.org/2001/XMLSchema#string

Francesco M Marincola

http://www.w3.org/2001/XMLSchema#string

Gail Deraffele

http://www.w3.org/2001/XMLSchema#string

Howard L Kaufman

http://www.w3.org/2001/XMLSchema#string

Marianna Sabatino

http://www.w3.org/2001/XMLSchema#string

Monica C Panelli

http://www.w3.org/2001/XMLSchema#string

Seunghee Kim-Schulze

http://www.w3.org/2001/XMLSchema#string

P2860

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture.

Tumor angiogenesis: therapeutic implications

Systematic variation in gene expression patterns in human cancer cell lines

Tumor angiogenesis

Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism

Inflammatory protein profile during systemic high dose interleukin-2 administration.

VEGF-integrin interplay controls tumor growth and vascularization.

Application of IL-2 and other cytokines in renal cancer.

P304

2645-2652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.1106

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19364969

http://www.w3.org/2001/XMLSchema#string

P921

P932

2689845

http://www.w3.org/2001/XMLSchema#string